Neumora Therapeutics, Inc. Common Stock
NMRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $668 | $0 | $0 |
| Gross Profit | $0 | -$668 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $200,927 | $142,719 | $104,749 | $212,776 |
| G&A Expenses | $62,537 | $45,475 | $31,121 | $24,547 |
| SG&A Expenses | $62,537 | $44,807 | $31,121 | $24,547 |
| Sales & Mktg Exp. | $0 | -$668 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $263,464 | $187,526 | $135,870 | $237,323 |
| Operating Income | -$263,464 | -$188,194 | -$135,870 | -$237,323 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $19,855 | -$47,463 | $4,966 | $11 |
| Pre-Tax Income | -$243,609 | -$235,657 | -$130,904 | -$237,312 |
| Tax Expense | $178 | $268 | $0 | $0 |
| Net Income | -$243,787 | -$235,925 | -$130,904 | -$237,312 |
| % Margin | – | – | – | – |
| EPS | -1.53 | -1.49 | -0.86 | -1.56 |
| % Growth | -2.7% | -73.3% | 44.9% | – |
| EPS Diluted | -1.53 | -1.49 | -0.86 | -1.56 |
| Weighted Avg Shares Out | 159,377 | 158,832 | 151,949 | 151,949 |
| Weighted Avg Shares Out Dil | 159,377 | 158,832 | 151,949 | 151,949 |
| Supplemental Information | – | – | – | – |
| Interest Income | $19,933 | $16,611 | $4,561 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $631 | $668 | $594 | $538 |
| EBITDA | -$262,833 | -$187,526 | -$135,276 | -$236,785 |
| % Margin | – | – | – | – |